Shilpa Medicare Ltd

Shilpa Medicare Ltd Share Price Today: Live Updates & Key Insights

Get insights on Shilpa Medicare Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Shilpa Medicare Ltd Share Price Chart

Shilpa Medicare Ltd Fundamentals

Traded Volume: 1,30,310

Market Cap(Cr): 6,857

Avg Traded Price 352.19

1 Year return -25.09%

Upper Circuit 356.2

Lower Circuit 349.1

P/E TTM 50.00

P/B Ratio 7.00

Traded Value(Cr) 456.87

EPS TTM 7.017

Book value 7.017

Dividend 0.00%

Shilpa Medicare Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Shilpa Medicare Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Shilpa Medicare Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -10.22%

1M -2.96%

3M -18.20%

1Y -25.09%

YTD -12.84%

Shilpa Medicare Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Shilpa Medicare Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 1.12L

Day Before Yesterday 2.34L

1W Avg 2.39L

1M Avg 2.93L

3M Avg 2.04L

Shilpa Medicare Ltd Technical Details

Shilpa Medicare Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 348

Support 2 345

Support 3 341

Pivot Point : 352

Resistance 1 355

Resistance 2 359

Resistance 3 362

Shilpa Medicare Ltd Corporate Actions

Shilpa Medicare Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Shilpa Medicare Ltd’s capital allocation strategies.

All

Ex-Date 03-Oct-2025 Type B Description share@1:1 Record Date 03-Oct-2025 Ratio 1:1

Ex-Date 17-Sep-2025 Type D Description 1.00/share@100.00% Record Date 17-Sep-2025 Ratio 100.00

Ex-Date 19-Sep-2022 Type D Description 1.10/share@110.00% Record Date 20-Sep-2022 Ratio 110.00

Ex-Date 20-Sep-2021 Type D Description 1.10/share@110.00% Record Date - Ratio 110.00

Ex-Date 16-Mar-2020 Type D Description 1.10/share@110.00% Record Date 17-Mar-2020 Ratio 110.00

Ex-Date 12-Sep-2019 Type D Description 1.00/share@100.00% Record Date - Ratio 100.00

Ex-Date 01-Mar-2018 Type D Description 0.70/share@70.00% Record Date 05-Mar-2018 Ratio 70.00

Ex-Date 21-Mar-2017 Type D Description 0.60/share@60.00% Record Date 22-Mar-2017 Ratio 60.00

Ex-Date 28-Mar-2016 Type D Description 0.60/share@60.00% Record Date 29-Mar-2016 Ratio 60.00

Ex-Date 06-Nov-2015 Type S Description share@1:2.00 Record Date 09-Nov-2015 Ratio 1:2.00

Ex-Date 16-Sep-2015 Type D Description 1.10/share@55.00% Record Date - Ratio 55.00

Ex-Date 11-Sep-2014 Type D Description 1.00/share@50.00% Record Date - Ratio 50.00

Ex-Date 16-Jul-2013 Type D Description 1.30/share@65.00% Record Date - Ratio 65.00

Ex-Date 16-Jul-2013 Type B Description share@1:2 Record Date - Ratio 1:2

Ex-Date 17-Sep-2012 Type D Description 0.90/share@45.00% Record Date - Ratio 45.00

Ex-Date 15-Sep-2011 Type D Description 0.80/share@40.00% Record Date - Ratio 40.00

Ex-Date 16-Sep-2010 Type D Description 0.70/share@35.00% Record Date - Ratio 35.00

Ex-Date 24-Sep-2009 Type D Description 0.50/share@25.00% Record Date - Ratio 25.00

Ex-Date 11-Sep-2008 Type D Description 0.40/share@20.00% Record Date - Ratio 20.00

Ex-Date 28-Sep-2007 Type S Description share@1:5.00 Record Date 08-Oct-2007 Ratio 1:5.00

Ex-Date 24-May-2007 Type D Description 2.00/share@20.00% Record Date 26-May-2007 Ratio 20.00

Dividends

Announcement Date 17-Sep-2025 Ex Dividend Date 17-Sep-2025 Dividend(%) 100

Announcement Date 19-Sep-2022 Ex Dividend Date 19-Sep-2022 Dividend(%) 110

Announcement Date 20-Sep-2021 Ex Dividend Date 20-Sep-2021 Dividend(%) 110

Announcement Date 16-Mar-2020 Ex Dividend Date 16-Mar-2020 Dividend(%) 110

Announcement Date 12-Sep-2019 Ex Dividend Date 12-Sep-2019 Dividend(%) 100

Announcement Date 01-Mar-2018 Ex Dividend Date 01-Mar-2018 Dividend(%) 70

Announcement Date 21-Mar-2017 Ex Dividend Date 21-Mar-2017 Dividend(%) 60

Announcement Date 28-Mar-2016 Ex Dividend Date 28-Mar-2016 Dividend(%) 60

Announcement Date 16-Sep-2015 Ex Dividend Date 16-Sep-2015 Dividend(%) 55

Announcement Date 11-Sep-2014 Ex Dividend Date 11-Sep-2014 Dividend(%) 50

Announcement Date 16-Jul-2013 Ex Dividend Date 16-Jul-2013 Dividend(%) 65

Announcement Date 17-Sep-2012 Ex Dividend Date 17-Sep-2012 Dividend(%) 45

Announcement Date 15-Sep-2011 Ex Dividend Date 15-Sep-2011 Dividend(%) 40

Announcement Date 16-Sep-2010 Ex Dividend Date 16-Sep-2010 Dividend(%) 35

Announcement Date 24-Sep-2009 Ex Dividend Date 24-Sep-2009 Dividend(%) 25

Announcement Date 11-Sep-2008 Ex Dividend Date 11-Sep-2008 Dividend(%) 20

Announcement Date 24-May-2007 Ex Dividend Date 24-May-2007 Dividend(%) 20

Bonus

Record Date 03-Oct-2025 Ex-Bonus Date 03-Oct-2025 Ratio 1:1

Record Date Ex-Bonus Date 16-Jul-2013 Ratio 1:2

Splits

Record Date 09-Nov-2015 Split Date 06-Nov-2015 Face Value (Before/After) 2.00/1.00

Record Date 08-Oct-2007 Split Date 28-Sep-2007 Face Value (Before/After) 10.00/2.00

Others

Rights No Rights has been declared by SHILPAMED

Shilpa Medicare Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Shilpa Medicare Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Shilpa Medicare Ltd's relative performance and valuation against major competitors.

Stock Name Marksans Pharma Ltd ₹191.73 (-0.69%) M. Cap (Cr) 86.89 1 Yr Return (%) -37.98% P/E (TTM) 24.71 PB Ratio 3.81

Stock Name Jeena Sikho Lifecare Ltd ₹691.90 (-3.37%) M. Cap (Cr) 86.00 1 Yr Return (%) +79.10% P/E (TTM) 55.87 PB Ratio 31.50

Stock Name Strides Pharma Science Ltd ₹895.05 (-3.07%) M. Cap (Cr) 82.50 1 Yr Return (%) +35.84% P/E (TTM) 20.77 PB Ratio 3.63

Stock Name Shilpa Medicare Ltd ₹350.60 (-1.60%) M. Cap (Cr) 68.57 1 Yr Return (%) -25.09% P/E (TTM) 49.96 PB Ratio 2.89

Stock Name FDC Ltd ₹411.00 (-0.71%) M. Cap (Cr) 66.91 1 Yr Return (%) -15.35% P/E (TTM) 29.68 PB Ratio 2.93

Stock Name Akums Drugs & Pharmaceuticals Ltd ₹421.65 (+0.02%) M. Cap (Cr) 66.37 1 Yr Return (%) NaN% P/E (TTM) 20.93 PB Ratio 2.18

Shilpa Medicare Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Shilpa Medicare Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 -19.06 Mar 2024 8.03 Mar 2023 2.08 Mar 2022 173.87 Mar 2021 69.63

PARTICULARS Investing Activities Mar 2025 -433.29 Mar 2024 155.82 Mar 2023 -94.80 Mar 2022 -378.97 Mar 2021 -238.13

PARTICULARS Financing Activities Mar 2025 450.09 Mar 2024 -163.07 Mar 2023 87.68 Mar 2022 97.23 Mar 2021 255.58

PARTICULARS Net Cash Flow Mar 2025 -0.04 Mar 2024 0.78 Mar 2023 -5.04 Mar 2022 -107.88 Mar 2021 87.08

Shilpa Medicare Ltd Shareholding Pattern

This shows the ownership breakdown of Shilpa Medicare Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 44.23%

Public 37.18%

Other Institutions 3.41%

FII 10.92%

Mutual Funds 4.26%

About Shilpa Medicare Ltd

Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987. The Company changed the status to Public and the name of the Company changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service. The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka. It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology. It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. While SML's underlying expertise is in the field of oncology, it also derives revenue from sale of non-oncology APIs. With key products being Ambroxol (Mucolytic Agent) in Europe and Tranexmic Acid and Ursodeoxycholic Acid in India.SML deals in high-quality Active Pharmaceutical Ingredients (APIs), Bulk drug, Intermediates, Formulations and Development service, New Drug Delivery Systems, Peptides / Biotech products and Specialty Chemicals etc. using sophisticated technology meticulously in order to comply with laid down international standards/specifications. SML is among the world's leading suppliers of Oncology/Non-Oncology APIs and intermediates.In year 1992, the company installed production facilities to manufacture sodium methoxide. During FY 2015, projects of five products transfer executed successfully, other projects of eight products have been completed and ready for transfer to plant. Ten new molecules have been taken for development considering future demand.During FY15, as part of mobilization of resources for the purpose of expanding the operations of the Company, fresh funds were raised by allotting 17,64,705 equity shares of Rs.2/- each to Tano Mauritius India FVCI II, the existing member of the Company, at a premium of Rs 423/-each on 15 May 2014 on preferential basis.During FY2016, the company after obtaining the approval of members at the 28th Annual General Meeting held on 28 September, 2015, divided the face value of existing equity share of Rs.2/- into two equity shares of Re.1/- each fully paid-up, with effect from the Record Date specified. Raichem Medicare Pvt Ltd., a subsidiary of Shilpa Medicare, completed installation of all machineries during the FY 2015-2016 and recruited all the key personnel, also commenced trial production in August 2015 after the Audit by External Consultant from Italy and started commercial production in December-2015. The subsidiary obtained the Drug Manufacturing license and GMP certificate and consent from pollution control board for operating the plant. In FY 16-17, Shilpa Medicare launched the generic versions of Vidaza Injection & Xeloda Tablets. During the year under review, as part of mobilization of resources for the purpose of expanding the operations of the company, fresh funds were raised by allotting 30,25,000 equity shares of Re.1/- each to TA FII Investors Limited, at a premium of Rs.569/- each on 26 December, 2016 on preferential basis.Pursuant to the order dated 24 November 2017 of Hon'ble National Company Law Tribunal, Bangalore Bench, the Navya Biologicals Private Limited was merged with the Company effective from 1 April, 2016. In FY 2019, the company incorporated Shilpa Pharma Inc. as a wholly owned subsidiary in USA. During the current FY 2019-20, the Company formed Sravathi Advance Process Technologies Private Limited to foray into the R&D activities of specific drug processes by roping prominent technocrats. It launched the Indian branded generic of Ibrutinib, an anti-cancer drug under the brand name 'IBRUSHIL'. During the financial year 2019-2020, Shilpa launched Azacitidine, covering the majority of European countries. It launched the first Indian Branded Generic of Lenvatinib Mesylate under the brand name Lenshil which is used for the treatment of differentiated thyroid cancer (DTC) and hepatocellular carcinoma. It sold 26% stake and exited from in Raichem Medicare Private Limited, erstwhile Joint Venture, in the month of June, 2020. It incorporated Shilpa Albumin Private Limited and Shilpa Biologicals Private Limited as Wholly Owned Subsidiaries of the Company.In 2021, the Company launched a pediatric dose paracetamol oral thin film, under the brand name 'Molshil' in strengths of 60 mg and 120 mg. It commissioned the State of Art Centralized Finished Dosages R&D Centre at Dabaspet near Bangalore. In 2021, Shilpa Biologicals Pvt Ltd, (SBPL), a wholly owned subsidiary of Company signed an agreement with Dr. Reddy's Laboratories for production-supply of Sputnik V vaccine from its integrated Biologics R&D cum manufacturing center at Dharwad, Karnataka. It formed Sravathi AI Technology Private Limited, Shilpa Corporate Holdings Private Limited and Koanna Helathcare, Cananda. In FY 2022, the Company commissioned a combo line for ODF/TDS.During the year 2021-22, Shilpa Corporate holdings Private Limited an investment company, has been formed as a wholly ownedsubsidiary, which acquired 100% stake in FTF Pharma Private Limited an an integrated drug development company, Koanaa Healthcare Canada, Koanaa International FZ LLC (Dubai), Indo Biotech SDN. BHD Malaysia, and so that all these companies have become as wholly Owned Subsidiaries. Further, the Company acquired balance 25% equity shares of INM Technologies Private Limited and made a wholly owned subsidiary. INM Technologies Private Limited which is the wholly owned subsidiary of the Company holds 25% of its stake in INM Nuvent Paints Private Limited. The Company had disposed off the total stake in Loba Feinchemie Gmbh, a step down subsidiary in Austria. In 2022, the Company launched 12 formulations in India. The new launches were in the therapeutic areas of oncology, non-oncology, and products for the OTC market such as women hygiene, vitamin supplements and an antioxidant green tea film. It commissioned new R&D center for polymer & peptide, created separate wing for CDMO.The Company launched its first NDA product in the US market, in partnership with Amneal in FY 2024. It launched first biological product High Concentration Adalimumab in Indian market for the biological business. ODF products in the nutraceutical space launched in the US market. The Company established a state-of-the-art manufacturing and R&D facility in Dharwad, Karnataka, designed to fulfil varied biosimilar production needs, including those for mammalian, microbial and fermentation products in 2024. Further, it launched PemetrexedRTU, first NDA product in the US markets,During the year 2025, Company received European CEPs for 2 Peptide products and secured a significant value contract in Polymers category. New APIs, including complex molecules like Nilotinib Base launched in FY25. The Company got approval through its JV Company for first oral fluid formulation, Imatinib particularly for paediatric and geriatric populations in FY25. The Company formed strategic partnership with Orion Corporation for the European commercialization of Recombinant Human for therapeutic use (rHA).

Chairman (Non-Executive)

Omprakash Inani

Registered office #12-6-214/A1, Hyderabad Road, Raichur, Karnataka, 584135

FAX :91-8532-238704

Background

Incorporation Year 1987

Face Value ₹1.00

Market Lot 1

Shilpa Medicare Ltd Latest News

VIEW MORE NEWS

FAQs on Shilpa Medicare Ltd